Amgen, Inc. (AMGN) Shares Bought by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp boosted its position in Amgen, Inc. (NASDAQ:AMGN) by 1.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 23,544 shares of the medical research company’s stock after acquiring an additional 355 shares during the period. Amgen accounts for approximately 1.7% of UNIVEST FINANCIAL Corp’s portfolio, making the stock its 11th largest holding. UNIVEST FINANCIAL Corp’s holdings in Amgen were worth $4,583,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in AMGN. Capital International Investors raised its stake in Amgen by 301.4% in the 3rd quarter. Capital International Investors now owns 11,093,182 shares of the medical research company’s stock valued at $2,299,506,000 after acquiring an additional 8,329,861 shares during the period. Capital World Investors bought a new stake in Amgen in the 3rd quarter valued at about $952,900,000. FMR LLC raised its stake in Amgen by 4.4% in the 3rd quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock valued at $7,425,805,000 after acquiring an additional 1,505,266 shares during the period. AQR Capital Management LLC raised its stake in Amgen by 36.2% in the 3rd quarter. AQR Capital Management LLC now owns 2,907,575 shares of the medical research company’s stock valued at $602,711,000 after acquiring an additional 773,506 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its stake in Amgen by 54.8% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 1,075,050 shares of the medical research company’s stock valued at $222,847,000 after acquiring an additional 380,562 shares during the period. Institutional investors and hedge funds own 76.86% of the company’s stock.

Several brokerages have recently weighed in on AMGN. Goldman Sachs Group reiterated a “buy” rating and set a $232.00 price target on shares of Amgen in a research report on Tuesday, December 4th. Morgan Stanley reiterated a “buy” rating and set a $213.00 price target on shares of Amgen in a research report on Tuesday, December 4th. Jefferies Financial Group reiterated a “buy” rating and set a $220.00 price target on shares of Amgen in a research report on Tuesday, December 4th. Royal Bank of Canada reiterated a “neutral” rating and set a $182.00 price target on shares of Amgen in a research report on Tuesday, December 4th. Finally, JPMorgan Chase & Co. set a $192.00 price target on Amgen and gave the company a “neutral” rating in a research report on Tuesday, December 4th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $205.51.

Shares of AMGN stock traded down $6.50 during trading on Thursday, hitting $184.26. The company had a trading volume of 57,922 shares, compared to its average volume of 3,324,577. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05. The stock has a market cap of $121.56 billion, a price-to-earnings ratio of 12.76, a price-to-earnings-growth ratio of 2.08 and a beta of 1.21. Amgen, Inc. has a 52 week low of $163.31 and a 52 week high of $210.19.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.26 by $0.16. The company had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 63.99%. During the same period in the prior year, the business earned $2.89 earnings per share. As a group, sell-side analysts forecast that Amgen, Inc. will post 13.93 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be given a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 3.15%. This is a boost from Amgen’s previous quarterly dividend of $1.32. The ex-dividend date is Thursday, February 14th. Amgen’s dividend payout ratio is 36.67%.

In other Amgen news, Director Tyler Jacks sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the completion of the sale, the director now owns 28,979 shares of the company’s stock, valued at $5,662,786.39. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link . Also, SVP Cynthia M. Patton sold 1,777 shares of the company’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the sale, the senior vice president now directly owns 23,090 shares of the company’s stock, valued at approximately $4,684,499.20. The disclosure for this sale can be found here . 0.27% of the stock is currently owned by corporate insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN) Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *